Mihnea P. Dragomir
YOU?
Author Swipe
View article: Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets
Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets Open
High-grade serous ovarian cancer (HGSOC) is often detected at an advanced stage, where curative treatment options are limited. Recent advances in ultrasensitive mass spectrometry-based spatial proteomics have provided a unique opportunity …
View article: AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer Open
Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multipl…
View article: Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S10 displays differences in celltypes between the cohorts A) for LTS and B) for STS based on CIBERSORT results.
View article: Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
The Table S1 shows the Patient ID, Cancer Stage and the Residual _Tumor status of the TCGA paired cohort grouped by the Survival Group.
View article: Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S4 displays the characteristics and subtypes of the Charité cohort.
View article: Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.
View article: Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S1 shows a REMARK Diagram of the Charité Cohort construction.
View article: Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S2 displays the Proportions of Molecular subtypes of LTS and STS in the Charité cohort and n the TCGA cohort.
View article: Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Purpose:The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify …
View article: Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S5 shows Candidate Genes in the Charité Cohort and Correlations among candidate genes and Literature research results for candidate genes.
View article: Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S7 shows the Mutation Landscape of TCGA LTS and STS Patients.
View article: Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S6 presents Boxplots showing differences in BRCA1/2, KRAS, RB1, CCNE1 expression between LTS and STS in the Charité cohort.
View article: Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S3 shows the likelihoods estimated by ConsensusOV for the subtypes of Charité STS and LTS.
View article: Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S2 shows the settings for digital image analysis in QuPath for the three IHC markers (CD3,CD4, CD8)
View article: Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.
View article: Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S3 shows the Gene count Distribution before and after quality filtering in the Charité Cohort and in the TCGA subcohort.
View article: Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S9 shows CIBERSORT estimated celltypes per sample in the Charité cohort and in the TCGA cohort.
View article: Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S4 shows the results of the DEG Analysis in the TCGA cohort A. DEGs in the TCGA (red = up in STS, blue = up in LTS) cohort B. Volcano plot
View article: Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids
Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids Open
Patient-Derived Organoids (PDOs) represent a promising technology for therapy prediction in pancreatic cancer, with the potential of enhancing treatment outcomes and allowing more effective, personalized treatment choices. However, classif…
View article: DNA methylation profile to aid in the diagnosis of pancreatic ductal adenocarcinoma and its role in disease progression
DNA methylation profile to aid in the diagnosis of pancreatic ductal adenocarcinoma and its role in disease progression Open
There is no immunohistochemical or molecular marker to confirm the histologic diagnosis of pancreatic ductal adenocarcinoma (PDAC). This is particularly important in a scenario of unknown primary. Molecularly, PDAC is characterized by a li…
View article: Mucinous cystic neoplasms of the pancreas and liver share a similar <scp>DNA</scp> methylation profile with mucinous ovarian tumors
Mucinous cystic neoplasms of the pancreas and liver share a similar <span>DNA</span> methylation profile with mucinous ovarian tumors Open
The origin of mucinous cystic neoplasms (MCNs) remains a major challenge in hepato‐pancreato‐biliary pathology. These cystic tumors are defined by their mucinous epithelium and ovarian‐like stroma, with an estimated 10% risk of progression…
View article: A quantitative tumor‐wide analysis of morphological heterogeneity of colorectal adenocarcinoma
A quantitative tumor‐wide analysis of morphological heterogeneity of colorectal adenocarcinoma Open
The intertumoral and intratumoral heterogeneity of colorectal adenocarcinoma (CRC) at the morphologic level is poorly understood. Previously, we identified morphological patterns associated with CRC molecular subtypes and their distinct mo…
View article: From benign appearance to malignant truth: a case report of mesenteric dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features
From benign appearance to malignant truth: a case report of mesenteric dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features Open
View article: Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signatures
Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signatures Open
Summary High-grade serous ovarian cancer (HGSOC) is a devastating disease that is frequently detected at an incurable stage. Advances in ultrasensitive mass spectrometry-based spatial proteomics have provided a unique opportunity to uncove…
View article: Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management
Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management Open
Muscle-invasive bladder cancer (MIBC) presents significant treatment challenges. Antibody-drug conjugates targeting human epidermal growth factor receptor 2 (HER2), trophoblast cell surface antigen 2 (TROP-2), and nectin cell adhesion mole…
View article: Intraventricular mass in a 52‐year‐old woman
Intraventricular mass in a 52‐year‐old woman Open
View article: The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers
The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers Open
The mutational landscape of phylogenetically ultraconserved elements (UCEs), especially those in noncoding DNAs (ncUCEs), and their functional relevance in cancers remain poorly characterized. Here, we perform a systematic analysis of whol…
View article: DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites Open
View article: Multi-Drug Pharmacotyping improves Therapy Prediction in Pancreatic Cancer Organoids
Multi-Drug Pharmacotyping improves Therapy Prediction in Pancreatic Cancer Organoids Open
Patient-Derived Organoids (PDOs) represent a promising technology for therapy prediction in pancreatic cancer, with the potential of enhancing treatment outcomes and allowing more effective, personalized treatment choices. However, classif…
View article: MRI-CEUS fusion-guided lymphatic mapping as a preoperative strategy for lymphedema patients undergoing lymphaticovenous anastomosis surgery
MRI-CEUS fusion-guided lymphatic mapping as a preoperative strategy for lymphedema patients undergoing lymphaticovenous anastomosis surgery Open
MRL-CEUS fusion demonstrates superior performance in the identification of lymphatic vessels for lymphedema.